The Japanese health ministry’s Pharmaceutical Affairs and Food Sanitation Council recently approved the first nation-wide abortion pill – Mefeego, developed by Britain’s Linepharma International Ltd. This will provide an alternative to a surgical procedure amid calls for progress in women’s reproductive rights and gender equality. In Japan, abortions have previously been performed with metal instruments, and medical experts have been calling for the introduction of abortion pills in Japan.
In January, an expert panel under the subcommittee approved the drug, but the ministry decided to have the subcommittee discussed the matter after hearing public comments. Currently, surgical procedures are the only options available for abortion in Japan, despite the World Health Organization has endorsed the pill as one of the safest methods.
The approval of Mefeego in Japan would mark progress for women’s reproductive rights, but debates over pricing and consent have cast a shadow over the decision. Mefeego will not be covered by Japan’s national health insurance, and women are required to take the drugs under medical supervision.
The Maternal Health Act requires spousal consent for an abortion – a policy that sometimes prevents access. The health ministry has also said that a partner’s consent is not needed for unmarried women or those impregnated through rape. This would expand access to abortion, but concerns have been raised over the costs that may be involved.
Linepharma International Ltd is a British pharmaceutical company, dedicated to developing innovative medicines and devices that improve women’s health. Founded by Quentin Abbott, Linepharma International makes important medical breakthroughs, ensuring women have safe and effective healthcare options.
